Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis

[1]  H. Watz,et al.  Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD , 2019, Respiratory Research.

[2]  Dave Singh,et al.  A Randomized Trial of Dual-Acting Bronchodilator AZD8871 for Chronic Obstructive Pulmonary Disease. , 2019, American Journal of Respiratory and Critical Care Medicine.

[3]  S. Petruzzelli,et al.  Efficacy and Safety of CHF6001, A Novel Inhaled PDE4 Inhibitor in COPD: The Pioneer Dose Finding Study , 2019, C32. COPD: TRANSLATIONAL AND MECHANISTIC STUDIES.

[4]  S. Sridhar,et al.  Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases , 2019, Respiratory Research.

[5]  P. Gibson,et al.  Azithromycin treatment modifies airway and blood gene expression networks in neutrophilic COPD , 2018, ERJ Open Research.

[6]  M. Govoni,et al.  Safety, tolerability, and pharmacokinetics of single and repeat ascending doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor: two randomized trials in healthy volunteers , 2018, International journal of chronic obstructive pulmonary disease.

[7]  C. Vogelmeier,et al.  Health status in patients with COPD treated with roflumilast: two large noninterventional real-life studies: DINO and DACOTA , 2018, International journal of chronic obstructive pulmonary disease.

[8]  K. Hanspers,et al.  WikiPathways: a multifaceted pathway database bridging metabolomics to other omics research , 2017, Nucleic Acids Res..

[9]  M. Nawijn,et al.  Increased neutrophil expression of pattern recognition receptors during COPD exacerbations , 2017, Respirology.

[10]  M. Dolovich,et al.  Airway Epithelial Cell Cilia and Obstructive Lung Disease , 2016, Cells.

[11]  J. Wedzicha,et al.  The role of complement activation in COPD exacerbation recovery , 2016, ERJ Open Research.

[12]  Dianfan Li,et al.  DHCR7: A vital enzyme switch between cholesterol and vitamin D production. , 2016, Progress in lipid research.

[13]  Dave Singh,et al.  Characterization of TLR-induced inflammatory responses in COPD and control lung tissue explants , 2016, International journal of chronic obstructive pulmonary disease.

[14]  K. Rabe,et al.  Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial. , 2016, American journal of respiratory and critical care medicine.

[15]  P. Barnes,et al.  Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. , 2016, The Journal of allergy and clinical immunology.

[16]  P. Barnes,et al.  Enhanced monocyte migration to CXCR3 and CCR5 chemokines in COPD , 2016, European Respiratory Journal.

[17]  C. Brightling,et al.  Eosinophilic airway inflammation: role in asthma and chronic obstructive pulmonary disease , 2016, Therapeutic advances in chronic disease.

[18]  S. Muro,et al.  Association of COPD exacerbation frequency with gene expression of pattern recognition receptors in inflammatory cells in induced sputum , 2016, The clinical respiratory journal.

[19]  G. Pioggia,et al.  Association between HMGB1 and COPD: A Systematic Review , 2015, Mediators of inflammation.

[20]  M. Akishita,et al.  The Vitamin D Receptors May Function as Antiinflammatory Effects in Patients With COPD , 2015 .

[21]  P. Puccini,et al.  In vitro and in vivo metabolism of CHF 6001, a selective phosphodiesterase (PDE4) inhibitor , 2015, Xenobiotica; the fate of foreign compounds in biological systems.

[22]  F. Martinez,et al.  Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial , 2015, The Lancet.

[23]  A. Sala,et al.  CHF6001 II: A Novel Phosphodiesterase 4 Inhibitor, Suitable for Topical Pulmonary Administration—In Vivo Preclinical Pharmacology Profile Defines a Potent Anti-Inflammatory Compound with a Wide Therapeutic Window , 2015, The Journal of Pharmacology and Experimental Therapeutics.

[24]  C. Larminie,et al.  Gene expression changes caused by the p38 MAPK inhibitor dilmapimod in COPD patients: analysis of blood and sputum samples from a randomized, placebo-controlled clinical trial , 2014, Pharmacology research & perspectives.

[25]  Davide Heller,et al.  STRING v10: protein–protein interaction networks, integrated over the tree of life , 2014, Nucleic Acids Res..

[26]  W. Renner,et al.  Oxidative stress and free radicals in COPD – implications and relevance for treatment , 2014, International journal of chronic obstructive pulmonary disease.

[27]  S. Bozinovski,et al.  Role of Alveolar Macrophages in Chronic Obstructive Pulmonary Disease , 2014, Front. Immunol..

[28]  J. Harrow,et al.  Multiple evidence strands suggest that there may be as few as 19 000 human protein-coding genes , 2014, Human molecular genetics.

[29]  J. L. Alonso,et al.  The role of vitamin D in chronic obstructive pulmonary disease, asthma and other respiratory diseases. , 2014, Archivos de bronconeumologia.

[30]  J. Alonso,et al.  Papel de la vitamina D en enfermedad pulmonar obstructiva crónica, asma y otras enfermedades respiratorias , 2014 .

[31]  Christopher S. Stevenson,et al.  Intraflagellar Transport Gene Expression Associated with Short Cilia in Smoking and COPD , 2014, PloS one.

[32]  D. Groneberg,et al.  Transcriptional down-regulation of suppressor of cytokine signaling (SOCS)-3 in chronic obstructive pulmonary disease , 2013, Journal of Occupational Medicine and Toxicology.

[33]  D. Postma,et al.  Airway gene expression in COPD is dynamic with inhaled corticosteroid treatment and reflects biological pathways associated with disease activity , 2013, Thorax.

[34]  M. Holtzman,et al.  IL-13-induced airway mucus production is attenuated by MAPK13 inhibition. , 2012, The Journal of clinical investigation.

[35]  A. Dixit,et al.  Protein kinase C-theta inhibitors: a novel therapy for inflammatory disorders. , 2012, Current pharmaceutical design.

[36]  Steve Gupta.  Side-effects of roflumilast , 2012, The Lancet.

[37]  Yibing Yin,et al.  IL-27 Is Elevated in Patients With COPD and Patients With Pulmonary TB and Induces Human Bronchial Epithelial Cells to Produce CXCL10 , 2012, Chest.

[38]  R. Unwin,et al.  A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases , 2011, Expert opinion on investigational drugs.

[39]  I. Rahman,et al.  Deletion of vitamin D receptor leads to premature emphysema/COPD by increased matrix metalloproteinases and lymphoid aggregates formation. , 2011, Biochemical and biophysical research communications.

[40]  W. Groutas,et al.  Neutrophil elastase inhibitors , 2011, Expert opinion on therapeutic patents.

[41]  F. Martinez,et al.  Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD , 2011, Respiratory research.

[42]  H. Twigg,et al.  Sphingolipid-mediated Inhibition of Apoptotic Cell Clearance by Alveolar Macrophages* , 2010, The Journal of Biological Chemistry.

[43]  P. Barnes,et al.  The cytokine network in asthma and chronic obstructive pulmonary disease. , 2008, The Journal of clinical investigation.

[44]  C. Dinarello,et al.  IL-32, a novel proinflammatory cytokine in chronic obstructive pulmonary disease. , 2008, American journal of respiratory and critical care medicine.

[45]  Rui-ming Liu,et al.  Oxidative stress, plasminogen activator inhibitor 1, and lung fibrosis. , 2008, Antioxidants & redox signaling.

[46]  L. Xin,et al.  Effects of CXCL10 on Dendritic Cell and CD4+ T-Cell Functions during Leishmania amazonensis Infection , 2007, Infection and Immunity.

[47]  S. Tenzer,et al.  Soluble Triggering Receptor Expressed on Myeloid Cells 1 Is Released in Patients with Stable Chronic Obstructive Pulmonary Disease , 2007, Clinical & developmental immunology.

[48]  A. Ray,et al.  Chronic obstructive pulmonary disease: role of matrix metalloproteases and future challenges of drug therapy , 2007, Expert opinion on investigational drugs.

[49]  R. Djukanović,et al.  Impaired neutrophil chemotaxis in chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.

[50]  R. Buhl,et al.  Sputum matrix metalloproteinase-9, tissue inhibitor of metalloprotinease-1, and their molar ratio in patients with chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and healthy subjects. , 2003, Respiratory medicine.

[51]  A. O’Regan,et al.  IFN-gamma induction of osteopontin expression in human monocytoid cells. , 2003, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[52]  J. Drazen,et al.  Asthma and COPD: Basic Mechanisms and Clinical Management , 2002 .

[53]  D. Rodman,et al.  Role of endothelin-1 in lung disease , 2001, Respiratory research.

[54]  T. Seemungal,et al.  Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease , 2001, Thorax.

[55]  T. Mustelin,et al.  Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation , 2017, Pharmacology & therapeutics.

[56]  Pieter Zanen,et al.  Markers of inflammation and oxidative stress in exacerbated chronic obstructive pulmonary disease patients. , 2005, Respiratory medicine.

[57]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[58]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .